he National Institute of Health and Clinical Excellence (NICE) has published new guidance for the month of February 2012. This month there is one technology appraisal that impact upon primary care.
Exenatide prolonged release (Bydureon®) has been reviewed in a technology appraisal and is approved for use in combination with oral therapies when glycaemic control is inadequate (HbA1c > 7.5% or 59mmol/mol) and:
- BMI ≥ 35kg/m2 and psychological or medical problems associated with high body weight
- BMI < 35kg/m2 and insulin therapy would have significant occupational implications or weight loss would benefit obesity-related comorbidities
It is also advised the treatment is reviewed at 6 months and discontinued if there has not been a reduction in HbA1c of 1% or 11mmol/mol.
Wednesday, February 22, 2012
NICE Guidance – February 2012
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment